Aldeyra Therapeutics Advances Investigational Oral RASP Modulator ADX‑629 Into New Phase 2 Systemic Disease TrialsBusiness Wire • 02/16/23
Aldeyra Therapeutics to Participate in Fireside Chat at the SVB Securities Global Biopharma ConferenceBusiness Wire • 02/09/23
Aldeyra Therapeutics Announces FDA Acceptance of New Drug Application for Reproxalap for the Treatment of Dry Eye DiseaseBusiness Wire • 02/07/23
Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for ADX‑2191 for the Treatment of Primary Vitreoretinal LymphomaBusiness Wire • 12/21/22
Aldeyra Therapeutics' Investigational RASP Modulator ADX-629 Improved Signs of Intoxication in Alcohol Challenge Phase 2 Clinical TrialBusiness Wire • 12/13/22
Aldeyra Therapeutics Announces Positive Primary Vitreoretinal Lymphoma Pre-NDA Meeting with the FDABusiness Wire • 12/01/22
Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for Reproxalap for the Treatment of Signs and Symptoms of Dry Eye DiseaseBusiness Wire • 11/29/22
Aldeyra Therapeutics Reports Third-Quarter 2022 Financial Results and Recent Corporate HighlightsBusiness Wire • 11/10/22
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Third-Quarter 2022 Financial Results and Discuss Recent Corporate HighlightsBusiness Wire • 11/03/22
Aldeyra Therapeutics Announces Oral Presentation of Phase 3 Data at the American Academy of Optometry 2022 Annual MeetingBusiness Wire • 10/26/22
Aldeyra Therapeutics Achieves Primary Endpoint in Part 1 of Phase 3 GUARD Trial of ADX-2191 in Proliferative VitreoretinopathyBusiness Wire • 10/06/22
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative VitreoretinopathyBusiness Wire • 10/05/22
Aldeyra Therapeutics Announces Positive Dry Eye Disease Pre-NDA Meeting with the FDA and Highlights Upcoming Corporate MilestonesBusiness Wire • 09/14/22
Aldeyra Therapeutics, Inc. (ALDX) Now Trades Above Golden Cross: Time to Buy?Zacks Investment Research • 08/15/22
Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/05/22
Aldeyra Therapeutics Reports Second-Quarter 2022 Financial Results and Recent Corporate HighlightsBusiness Wire • 08/05/22
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Second-Quarter 2022 Financial Results and Discuss Recent Corporate HighlightsBusiness Wire • 07/29/22
Aldeyra's Reproxalap Hits Primary Goals In Dry Eye Disease Chamber Crossover TrialBenzinga • 07/12/22
Aldeyra Therapeutics Achieves Primary Endpoints in Dry Eye Disease Chamber Crossover Clinical TrialBusiness Wire • 07/12/22